News & Publications

Stanford Medicine News: Cancer

  • Cancer therapy may work in unexpected way

    An antibody to the cell receptor PD-1 may launch a two-pronged assault on cancer by initiating attacks by both T cells and macrophages, a Stanford study has found.

  • Study finds first possible drug treatment for lymphedema

    Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it.

  • Fibrosis reversed when ‘don’t eat me’ signal blocked

    A common signaling pathway unites diverse fibrotic diseases in humans, Stanford researchers have found. An antibody called anti-CD47, which is being tested as an anti-cancer agent, reverses fibrosis in mice.

  • Physicians’ misunderstanding of genetic test results may hamper mastectomy decisions for breast cancer patients

    Women with breast cancer do not receive timely genetic testing or have adequate access to effective genetic counseling, which may compromise treatment decisions, according to research from Stanford and the University of Michigan.

A look at Stanford Cancer Institute’s survivorship program

“Survivorship” is the popular term for a wide range of care and support strategies intended to maximize quality of life during and after cancer treatment, whether the treatment ultimately proves successful or not. The Stanford Cancer Institute has initiated an integrated Cancer Survivorship Program that coordinates multiple patient and family support services to deliver individualized care to every cancer patient at Stanford.

Cancer clinical trials: Stanford strives to enroll more diverse participants

Very few cancer patients participate in clinical trials and many aren’t even aware that they qualify for one. In order to advance cancer research, more participants are needed — especially ethnic and racial minorities who are vastly underrepresented in clinical trials. This is particularly important for diseases that occur more frequently or appear differently in non-white populations. For example, African American women have a 41 percent higher mortality rate for breast cancer than white woman, despite having a lower incidence rate, but only about 5 percent of clinical trial participants — for all diseases — are African American.

The Stanford Cancer Institute (SCI) knows this problem well.

The Promise and Pitfalls of Cancer Immunotherapy

The concept of corralling the body’s immune system to combat cancer has been around for decades but recently has emerged as one of the most promising avenues of treatment.

Earlier this year, Silicon Valley entrepreneur and philanthropist Sean Parker launched the new Parker Institute for Cancer Immunotherapy, investing $250 million in a multi-institution effort that includes Stanford Medicine. The lead investigator at Stanford is Crystal Mackall, MD, a pediatric oncologist and associate director of the Stanford Cancer Institute, who discussed the venture.


SCI News

A quarterly publication for patients and friends of the Stanford Cancer Institute.

SCI Bulletin

A monthly publication with timely information for the cancer researchers, physicians and staff who make up the membership of the Stanford Cancer Institute.

Cancer Letter

Inside information on current cancer research and drug development. (SUnet ID required)

MD Community Newsletter

This quarterly publication is designed to inform our colleagues in the medical community, and especially physicians who are considering treatment options for their patients with cancer, about current clinical trials and research studies available at the NCI-designated Stanford Cancer Institute.

Access Newsletter

A publication for our community physicians, Stanford Access offers you a look into the programs and faculty of Stanford Health Care. Learn about the latest diagnostics, treatment solutions and innovative procedures happening at Stanford.